Symptom burden, viral load, and antibody response to ancestral SARS-CoV-2 strain in an outpatient household cohort

Publication date: Oct 28, 2024

Background Early in the SARS-CoV-2 pandemic, description of COVID-19 illness among non-hospitalized patients was limited. Data from household cohorts can help reveal the full spectrum of disease and the potential for long-term sequelae, even in non-severe disease. Methods Daily symptom diaries were collected in a US household cohort of SARS-CoV-2 infection from April to November 2020, during the pre-COVID vaccine period. SARS-CoV-2 nasal viral loads were measured at study entry and weekly until day 21; serologic testing was performed at study entry and day 28. A subset of volunteers underwent an additional assessment 8-10 months later. Participants who met the criteria for early infection–testing antibody-negative at study entry but PCR-positive either at baseline or during follow-up–were included in this analysis (n=143). Results Daily symptoms were ascertained in 143 outpatients with acute COVID-19, including 60 index cases who sought testing and 83 of their household contacts. Asymptomatic cases comprised 16% (13/83) of SARS-CoV-2 infections detected among household contacts. Among 119 persons with mild or moderate illness, the number of symptoms peaked 3 or 4 days after symptom onset. Fever and anosmia occurred in nearly half of participants. Symptom severity was associated with increased age, viral load, and cardiovascular disease. Increased BMI was associated with a higher antibody level at day 28, independent of symptom severity. Those with a higher day 28 antibody level were more likely to develop symptoms consistent with post-acute sequelae of SARS-CoV-2 (PASC), also known as long COVID-19, 8-10 months later. Conclusions Fever, anosmia, as well as asymptomatic infection were common features of COVID-19 non-severe illness when the D614G variant circulated in the US, before the availability of vaccines or outpatient therapies. Antibody levels following acute infection were linked to the development of symptoms of PASC 8-10 months later.

PDF

Concepts Keywords
Diabetes Antibody
Ice Cov
Microbiology Covid
Viral Day
Entry
Household
Infection
Load
Participants
Preprint
Sars
Symptom
Symptoms
Testing
Viral

Semantics

Type Source Name
disease MESH Symptom burden
disease MESH viral load
disease MESH COVID-19
disease MESH sequelae
disease IDO symptom
pathway REACTOME SARS-CoV-2 Infection
drug DRUGBANK Methionine
disease MESH infection
disease MESH anosmia
disease MESH cardiovascular disease
disease MESH long COVID
disease MESH asymptomatic infection
disease IDO acute infection
disease MESH Infectious Diseases
disease MESH clinical course
disease MESH pneumonia
disease IDO host
disease MESH emergency
disease IDO assay
disease IDO blood
disease MESH sore throat
disease MESH chest pain
drug DRUGBANK Etoperidone
disease IDO primary infection
disease MESH dyspnea
disease MESH coronary artery disease
disease MESH hypertension
disease MESH diabetes mellitus
disease MESH asthma
pathway KEGG Asthma
disease IDO history

Download Document

(Visited 1 times, 1 visits today)